Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Melioli

Showing results (91-100 of 114) with videos related to

Pageof 12
Sort By:
The Laryngoscope|May 1, 1992
Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinomaG Melioli, G Margarino, M Scala, et al.
Cancer|July 15, 1996
A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinomaG B Ratto, P Zino, S Mirabelli, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1996
Phenotypic, functional and molecular analysis of lymphocytes associated with bladder cancerS Bruno, A M Machí, C Semino, et al.
Melanoma Research|April 1, 1994
Proliferative, phenotypic and functional and molecular characteristics of tumour-infiltrating lymphocytes obtained from unselected patients with malignant melanomas and expanded in vitro in the presence of recombinant interleukin-2G Melioli, M Guastella, C Semino, et al.
Acta Medica Austriaca|January 1, 1989
Intraperitoneal infusion of recombinant interleukin-2 in malignant ascites in patients with gastrointestinal and ovarian cancerS Bertoglio, G Melioli, E Baldini, et al.
European Journal of Immunology|December 1, 1987
CD3+4-8-WT31-(T cell receptor gamma+) cells and other unusual phenotypes are frequently detected among spontaneously interleukin 2-responsive T lymphocytes present in the joint fluid in juvenile rheumatoid arthritis. A clonal analysisA De Maria, M Malnati, A Moretta, et al.
Haematologica|January 1, 1984
Infections in a bone marrow transplant unit: analysis of 57 patientsA Bacigalupo, M T Van Lint, F Frassoni, et al.
American Journal of Clinical Oncology|June 1, 1991
A phase I study of recombinant interleukin-2 intraperitoneal infusion in patients with neoplastic ascites: toxic effects and immunologic resultsG Melioli, M R Sertoli, M Bruzzone, et al.
Clinical and Experimental Rheumatology|September 1, 1989
Phenotypic and functional characterization of human T lymphocytes expressing a gamma/delta T cell antigen receptorL Moretta, E Ciccone, M C Mingari, et al.
International Journal of Immunopathology and Pharmacology|January 11, 2012
Neo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase I/II pilot studyG B Ratto, R Costa, P Maineri, et al.
Pageof 12

Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
The Laryngoscope|May 1, 1992
Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinomaG Melioli, G Margarino, M Scala, et al.
Cancer|July 15, 1996
A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinomaG B Ratto, P Zino, S Mirabelli, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1996
Phenotypic, functional and molecular analysis of lymphocytes associated with bladder cancerS Bruno, A M Machí, C Semino, et al.
Melanoma Research|April 1, 1994
Proliferative, phenotypic and functional and molecular characteristics of tumour-infiltrating lymphocytes obtained from unselected patients with malignant melanomas and expanded in vitro in the presence of recombinant interleukin-2G Melioli, M Guastella, C Semino, et al.
Acta Medica Austriaca|January 1, 1989
Intraperitoneal infusion of recombinant interleukin-2 in malignant ascites in patients with gastrointestinal and ovarian cancerS Bertoglio, G Melioli, E Baldini, et al.
European Journal of Immunology|December 1, 1987
CD3+4-8-WT31-(T cell receptor gamma+) cells and other unusual phenotypes are frequently detected among spontaneously interleukin 2-responsive T lymphocytes present in the joint fluid in juvenile rheumatoid arthritis. A clonal analysisA De Maria, M Malnati, A Moretta, et al.
Haematologica|January 1, 1984
Infections in a bone marrow transplant unit: analysis of 57 patientsA Bacigalupo, M T Van Lint, F Frassoni, et al.
American Journal of Clinical Oncology|June 1, 1991
A phase I study of recombinant interleukin-2 intraperitoneal infusion in patients with neoplastic ascites: toxic effects and immunologic resultsG Melioli, M R Sertoli, M Bruzzone, et al.
Clinical and Experimental Rheumatology|September 1, 1989
Phenotypic and functional characterization of human T lymphocytes expressing a gamma/delta T cell antigen receptorL Moretta, E Ciccone, M C Mingari, et al.
International Journal of Immunopathology and Pharmacology|January 11, 2012
Neo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase I/II pilot studyG B Ratto, R Costa, P Maineri, et al.
Pageof 12